Category Archives: Genetics

Fulgent Genetics Announces Partnership with Ohio Department of Rehabilitation and Correction for COVID-19 TestingFulgent Genetics will provide routine…

TEMPLE CITY, Calif., Sept. 30, 2020 (GLOBE NEWSWIRE) -- Fulgent Genetics, Inc. (NASDAQ: FLGT) (Fulgent Genetics or the company), a technology company providing comprehensive testing solutions through its scalable technology platform, today announced that the Ohio Department of Rehabilitation and Correction (ODRC) has selected Fulgent Genetics for their COVID-19 testing needs.

The Ohio Department of Rehabilitation and Correction will leverage Fulgents RT-PCR testing capabilities and Enterprise Platform to test its approximately 14,000 employees on a routine basis. The partnership encompasses on-site testing at locations across the state and will leverage Fulgents Enterprise Platform. Fulgents platform will enable theODRC to streamline the on-site testing process by either giving each employee a QR code or using their employer ID which is linked to the individuals sample via a barcode scan, and then self-collected under supervision and returned to Fulgents lab for processing and reporting. Employees will receive their results within 24 hours of sample receipt.

We look forward to aiding the Ohio Department of Rehabilitation and Correction in their effort to protect their employees and curb the spread of COVID-19 across their facilities, commented Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. Our Enterprise Platform offering enables the ODRC to test their employees in an extremely efficient manner, a process that takes approximately one minute per person. This offering provides a flexible and comprehensive testing solution for the ODRC that utilizes our gold-standard RT-PCR testing capabilities. Fulgent continues to raise the bar in offering COVID-19 testing solutions that meet the needs of large organizations and municipalities in a highly efficient and accurate manner.

About Fulgent Genetics

Fulgent Genetics proprietary technology platform has created a broad, flexible test menu and the ability to continually expand and improve its proprietary genetic reference library while maintaining accessible pricing, high accuracy and competitive turnaround times. Combining next generation sequencing (NGS) with its technology platform, the company performs full-gene sequencing with deletion/duplication analysis in an array of panels that can be tailored to meet specific customer needs. In 2019, the company launched its first patient-initiated product, Picture Genetics, a new line of at-home screening tests that combines the companys advanced NGS solutions with actionable results and genetic counseling options for individuals. Since March 2020, the company has commercially launched several tests for the detection of SARS-CoV-2, the virus that causes the novel coronavirus (COVID-19), including NGS and reverse transcription polymerase chain reaction (RT-PCR) - based tests. The company has received Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) for the RT-PCR-based tests for the detection of SARS-CoV-2 using upper respiratory specimens (nasal, nasopharyngeal, and oropharyngeal swabs) and for the at-home testing service through Picture Genetics. A cornerstone of the companys business is its ability to provide expansive options and flexibility for all clients unique testing needs through a comprehensive technology offering including cloud computing, pipeline services, record management, web portal services, clinical workflow, sequencing as a service and automated lab services.

About Picture Genetics

Through its Picture Genetics platform launched in 2019, Fulgent Genetics offers consumers direct access to its advanced genetic testing and analytics capabilities from the ease and comfort of home, at an affordable price point. The Picture Genetics platform provides a holistic approach to at-home genetic screening by including oversight from independent physicians as well as genetic counseling options to complement Fulgent Genetics comprehensive genetic testing analysis. The Picture Genetics platform currently offers multiple tests, providing medically actionable, clinical-level results with professional medical follow-up in one easy process. Visit http://www.picturegenetics.com for more information.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Examples of forward-looking statements in this press release include statements about, among other things: managements beliefs, judgments and estimates regarding Fulgents testing solutions, including its technology platforms and RT-PCR testing solution; the companys identification and evaluation of opportunities and its ability to capitalize on opportunities to grow its business; and its expected lab capacity and results turnaround times.

Forward-looking statements are statements other than historical facts and relate to future events or circumstances or the companys future performance, and they are based on managements current assumptions, expectations and beliefs concerning future developments and their potential effect on the companys business. These forward-looking statements are subject to a number of risks and uncertainties, which may cause the forward-looking events and circumstances described in this press release to not occur, and actual results to differ materially and adversely from those described in or implied by the forward-looking statements. These risks and uncertainties include, among others: the ongoing impacts of the COVID-19 pandemic, including the preventive public health measures that may continue to impact demand for its tests and the pandemics effects on the global supply chain; the market potential for, and the rate and degree of market adoption of, the companys tests, including its newly-developed tests for COVID-19 and genetic testing generally; the companys ability to capture a sizable share of the developing market for genetic and COVID-19 testing and to compete successfully in these markets, including its ability to continue to develop new tests that are attractive to its various customer markets, its ability to maintain turnaround times and otherwise keep pace with rapidly changing technology; the companys ability to maintain the low internal costs of its business model, particularly as the company makes investments across its business; the companys ability to maintain an acceptable margin on sales of its tests, particularly in light of increasing competitive pressures and other factors that may continue to reduce the companys sale prices for and margins on its tests; risks related to volatility in the companys results, which can fluctuate significantly from period to period; risks associated with the composition of the companys customer base, which can fluctuate from period to period and can be comprised of a small number of customers that account for a significant portion of the companys revenue; the companys ability to grow and diversify its customer base and increase demand from existing and new customers; the companys investments in its infrastructure, including its sales organization and operational capabilities, and the extent to which these investments impact the companys business and performance and enable it to manage any growth it may experience in future periods; the companys level of success in obtaining coverage and adequate reimbursement and collectability levels from third-party payors for its tests; the companys level of success in establishing and obtaining the intended benefits from partnerships, joint ventures or other relationships; the companys compliance with the various evolving and complex laws and regulations applicable to its business and its industry; risks associated with the companys international operations; the companys ability to protect its proprietary technology platform; and general industry, economic, political and market conditions. As a result of these risks and uncertainties, forward-looking statements should not be relied on or viewed as predictions of future events.

The forward-looking statements made in this press release speak only as of the date of this press release, and the company assumes no obligation to update publicly any such forward-looking statements to reflect actual results or to changes in expectations, except as otherwise required by law.

The companys reports filed with the U.S. Securities and Exchange Commission (SEC), including its annual report on Form 10-K for the year ended December 31, 2019 filed with the SEC on March 13, 2020 and the other reports it files from time to time, including subsequently filed quarterly and current reports, are made available on the companys website upon their filing with the SEC. These reports contain more information about the company, its business and the risks affecting its business.

Investor Relations Contact:The Blueshirt GroupNicole Borsje, 415-217-2633; nborsje@blueshirtgroup.com

Media Contact:The Blueshirt GroupJeff Fox, 415-828-8298, jeff@blueshirtgroup.com

Visit link:
Fulgent Genetics Announces Partnership with Ohio Department of Rehabilitation and Correction for COVID-19 TestingFulgent Genetics will provide routine...

The aquatic chicken: tilapia genetics and their parallels with poultry – The Fish Site

When considering ongoing genetic improvement efforts in tilapia culture, comparisons with the development of the modern chicken industry often present themselves.

C Greg Lutz

Some 150 years ago, global poultry production looked quite a bit like tilapia production did in 1970. Chicken production was seasonal in many parts of the world because of climate and nutritional constraints, and it was a very fragmented industry, focusing mostly on local or regional markets. As a result, there were hundreds of localised chicken breeds and the culture of different birds in different localities was the norm.

Throughout the world the past century saw a shift from this fragmented industry, based on subsistence- and small-scale production, to vertically integrated facilities and specialised hatchery businesses with a focus on genetic improvement. This trend continues today, as industrial production expands in less developed nations.

The original focus of chicken breeders involved both egg and meat production in the same birds, but this shifted to separate breeding goals after World War I. At that point, production of meaty birds, known as broilers, became distinctly differentiated from that of the layers that supplied eggs. When broilers were first commercialised, mass selection was the approach used to improve production and meat yield. This resulted in moderate progress, because at the time most breeding flocks exhibited heritabilities ranging from 0.2 to 0.4.

In the tilapia industry the importance of meat yield is finally gaining more recognition as an important breeding goal. Heritabilities for fillet yield, ranging from 0.2 to 0.38 from 130 to 210 days of age, were reported in a population of Nile tilapia in Brazil (Turra et al. 2012) and a heritability of 0.25 was reported from Malaysia (Nguyen et al. 2010), but Gjerde et al. (2012) reported a much lower value of 0.06 for a line from Nicaragua. More recently, Yoshida et al. (2019) reported a modest increase in heritability estimates when using genomic information on a population in Costa Rica.

In chickens we see a negative correlation between growth and fecundity, so reproductive capacity is important in female lines, even when meat production is the ultimate goal. In tilapia improvement programmes, growth is also usually the breeding goal, but spawning success and frequency are critical considerations in commercial hatcheries. Heritability of spawning success was reported as 0.14 to 0.22 for a population of Nile tilapia in Vietnam, depending on the statistical model and spawning period.

In the years following World War II, chicken breeders began to cross distinct lines to produce broiler chicks. One reason was to maintain female lines that exhibited good egg production while crossing these with male lines that might be less productive as a result of intense selection for growth. This same practice occurs in many tilapia hatcheries around the world. Modern broiler production has evolved into a five-year process where four distinct lines are crossed to ultimately produce chicks. Crossing distinct lines is still not a common practice in tilapia production, but for a period of time hybrids were quite popular in China and also in Israel. At one time the breeding programme of a large tilapia operation in Honduras was based on a double crossing design similar to those used in the chicken industry.

Disease resistance has been an important component of chicken breeding programmes for many decades. In tilapia, a similar emphasis is taking hold. The recent emergence of tilapia lake virus (TiLV) has caused concern across the globe, but new research suggests breeding programmes to reduce or eliminate this threat may be possible. Using data from 124 O. niloticus families in Malaysia, researchers estimated heritabilities for TiLV resistance ranging from 0.48 to 0.56, with family survival ranging from 0 percent to 100 percent (Barria et al. 2020).

Some of the more long-standing tilapia pathogens are still causing major problems. Many tilapia hatcheries struggle with Flavobacterium columnare, the causative agent for columnaris disease. Selective breeding has been shown as a means to improve resistance to columnaris in tilapia, and this is important in tropical regions, where vaccines are not available and antibiotic resistance is on the rise. Researchers working with the Chitralada 4 strain in Thailand reported heritability estimates for columnaris resistance ranging from 0.14 to 0.30, based on different statistical models, with family survival rates ranging from 8 percent to 70 percent (Wonmongkol et al. 2017). Genetic influence over resistance to Streptococcus iniae and S. agalactiae have also been demonstrated, with heritabilities of 0.52 and 0.38, respectively, but resistance to one pathogen does not appear to confer resistance to the other (Shoemaker et al. 2016). Dr Carlos Lozano, with Spring Genetics, stated that selection for disease resistance is among the tilapia industrys top priorities for genetic improvement, adding In particular diseases like S. Iniae, S. agalactiae, Francisella,TiLV and columnaris.

C Greg Lutz

By the 1960s, chicken improvement programmes were emphasising the importance of feed conversion efficiency. This trait is quite difficult to measure in fish, but recent study demonstrated significant genetic control over it in Nile tilapia, with an estimated heritability of 0.32 (de Verdal et al. 2018). One genetic correlation with feed efficiency that was significant was weight loss at fasting (0.80), which would allow indirect selection for individuals with superior FCR while avoiding the complex task of measuring individual feed intake.

As quantitative genetic tools and selection programmes became more sophisticated, the chicken breeding sector began to consolidate, and most breeding programmes adopted selection indices that included more than 40 distinct physiological traits relating to feed efficiency, disease resistance, skeletal structure and behaviour. By the late 2000s only three major breeding companies dominated the market: Cobb-Vantress, Aviagen and Group Grimaud (a multi-species company based in Europe that also has interests in aquaculture species).

Over time, genetic improvement tools for chickens have evolved from mass selection, to index selection, to the use of BLUP estimates, to marker-assisted selection and now genomic selection is becoming the norm. When I asked Dr Lozano to cite some of the most important developments in tilapia improvement in recent years, he indicated: The recent development of SNP chips for tilapia has enabled the inclusion of marker assisted (MAS) and genomic selection in tilapia breeding programmes (eg Spring Genetics and GenoMar). This is especially important for disease resistance, where generally family selection was used and candidates were selected based on the performance of their siblings. With genomic selection we can select candidates based on their individual genetic merit. Gene-editing technologies have also recently been applied by AquaBounty and approved for Nile tilapia in Argentina.

Since there are so few genetic nuclei, modern industrial chicken lines must be adaptable to conditions found around the globe. Unlike a century ago, when any number of local chicken breeds could be found around the world, the birds being produced by these large corporations must incorporate adaptability to a variety of grow-out conditions and diets. This potential conflict between centralised breeding operations and a multitude of grow-out environments may eventually become an issue for tilapia producers as improved lines are disseminated across the globe. When asked about this, Dr Lozano commented: I envision the dissemination of superior genetics mostly to industrial scale producers. For small scale producers the low profit margin may restrict their accessibility to high quality fry.

Modern chickens are largely descended from the red jungle fowl, but at least one other related species appears to have contributed to the birds we raise today. Many lines of O. niloticus also include genetic contributions from other species. However, while the genome of the modern chicken has been relatively stable over the past century, this milestone is yet to be attained in tilapia. Not all tilapia are created equal. Researchers in Thailand used microsatellite genetic markers to examine changes in four lines of Nile tilapia (Oreochromis niloticus) derived from the genetically improved farmed tilapia (GIFT) strain, and in two lines derived from a local Chitralada strain. Three of the four GIFT-derived populations remained relatively pure, with no decline in genetic variation. However, one of the GIFT-derived populations showed high levels of introgression from the Chitralada strain, and the Chitralada-derived populations exhibited introgression from GIFT lines. Introgression from O. mossambicus was also observed in one of the Chitralada-derived lines and from O. aureus in one of the GIFT-derived lines (Sukmanomon et al. 2011).

C Espejo Genipez Viterbo

The situation regarding some semblance of genomic standardisation becomes even more complicated with red tilapia. In many parts of the world, consumers demand red-coloured fish. Although red colouration has been established in O. niloticus (the red Stirling line) through the isolation and propagation of a single red mutant (McAndrew et al. 1988, Hussain 1994), most strains of red tilapia include genetic contributions from several distinct species including slower-growing O. mossambicus and O. urolepis hornorum (Desprez et al. 2006). In recent years efforts to develop robust commercial lines of red O niloticus have advanced through backcrossing red Stirling fish with fast-growing strains such as GIFT and Chitralada (Lago et al. 2017). In Colombia, my colleague Carlos Espejo has adapted a similar strategy, crossing local red lines of multi-species ancestry with Chitralada-based wild-type fish.

Just as most unimproved varieties of chickens would not perform very well in commercial chicken houses, most industrial birds would not survive long in the farmyards of subsistence farmers around the globe. Many local varieties of chicken persist around the world, and leaving aside all the introgression and hybridisation that has occurred over the past century, even within pure O. niloticus a similar array of variation can be found in terms of local and regional strains. Africa as a whole is a region of concern in terms of conserving genetic resources scattered among hundreds of local stocks of Nile tilapia. In the case of chickens, many historically recognised European, Asian and North American breeds were already reported as extinct by the FAO in 2007, having been replaced by modern varieties. Many more breeds were listed as at risk at that time. However, in regions where subsistence farming still plays a significant role in food production, indigenous chicken breeds persist, due to their accumulated adaptation to local conditions. Hopefully the same will hold true for tilapia.

References available from the author.

His career has included experience with numerous aquatic species in a number of countries. Dr Lutz is also the author of the book Practical Genetics for Aquaculture.

The rest is here:
The aquatic chicken: tilapia genetics and their parallels with poultry - The Fish Site

Tragic Genetic Heritage: The Ancient Neanderthal Hand in Severe COVID-19 – SciTechDaily

By Okinawa Institute of Science and Technology Graduate UniversitySeptember 30, 2020

Since first appearing in late 2019, the novel virus, SARS-CoV-2, has had a range of impacts on those it infects. Some people become severely ill with COVID-19, the disease caused by the virus, and require hospitalization, whereas others have mild symptoms or are even asymptomatic.

There are several factors that influence a persons susceptibility to having a severe reaction, such as their age and the existence of other medical conditions. But ones genetics also plays a role, and, over the last few months, research by the COVID-19 Host Genetics Initiative has shown that genetic variants in one region on chromosome 3 impose a larger risk that their carriers will develop a severe form of the disease.

Now, a new study, published in Nature, has revealed that this genetic region is almost identical to that of a 50,000-year old Neanderthal from southern Europe. Further analysis has shown that, through interbreeding, the variants came over to the ancestors of modern humans about 60,000 years ago.

It is striking that the genetic heritage from Neanderthals has such tragic consequences during the current pandemic, said Professor Svante Pbo, who leads the Human Evolutionary Genomics Unit at the Okinawa Institute of Science and Technology Graduate University (OIST).

These genetic variants are almost completely absent in Africa and occur in the highest frequency in Bangladesh. Credit: Professor Svante Pbo and Professor Hugo Zeberg. This figure appeared in the publication in Nature.

Chromosomes are tiny structures that are found in the nucleus of cells and carry an organisms genetic material. They come in pairs with one chromosome in each pair inherited from each parent. Humans have 23 of these pairs. Thus, 46 chromosomes carry the entirety of our DNA millions upon millions of base pairs. And although the vast majority are the same between people, mutations do occur, and variations persist, at the DNA level.

The research by the COVID-19 Host Genetics Initiative looked at over 3,000 people including both people who were hospitalized with severe COVID-19 and people who were infected by the virus but werent hospitalized. It identified a region on chromosome 3 that influences whether a person infected with the virus will become severely ill and needs to be hospitalized.

The identified genetic region is very long, spanning 49.4 thousand base pairs, and the variants that impose a higher risk to severe COVID-19 are strongly linked if a person has one of the variants then theyre very likely to have all thirteen of them. Variants like these have previously been found to come from Neanderthals or Denisovans so Professor Pbo, in collaboration with Professor Hugo Zeberg, first author of the paper and a researcher at the Max Planck Institute for Evolutionary Anthropology and Karolinska Institutet, decided to investigate whether this was the case.

They found that a Neanderthal from southern Europe carried an almost identical genetic region whereas two Neanderthals from southern Siberia and a Denisovan did not.

Next, they questioned whether the variants had come over from Neanderthals or had been inherited by both Neanderthals and present-day people through a common ancestor.

If the variants had come from interbreeding between the two groups of people, then this would have occurred as recently as 50,000 years ago. Whereas, if the variants had come from the last common ancestor, they would have been around in modern humans for about 550,000 years. But random genetic mutations, and recombination between chromosomes, would have also occurred during this time and because the variants between the Neanderthal from southern Europe and present-day people are so similar over such a long stretch of DNA, the researchers showed that it was much more likely that they came from interbreeding.

Professor Pbo and Professor Zeberg concluded that Neanderthals related to the one from southern Europe contributed this DNA region to present-day people around 60,000 years ago when the two groups met.

Professor Zeberg explained that those who carry these Neanderthal variants have up to three times the risk of requiring mechanical ventilation. Obviously, factors such as your age and other diseases you may have also affect how severely you are affected by the virus. But among genetic factors, this is the strongest one.

The researchers also found that there are major differences in how common these variants are in different parts of the world. In South Asia about 50% of the population carry them. However, in East Asia theyre almost absent.

It is not yet known why the Neanderthal gene region is associated with increased risk of becoming severely ill. This is something that we and others are now investigating as quickly as possible, said Professor Pbo.

Reference: The major genetic risk factor for severe COVID-19 is inherited from Neanderthals by Hugo Zeberg and Svante Pbo, 30 September 2020, Nature.DOI: 10.1038/s41586-020-2818-3

See the original post here:
Tragic Genetic Heritage: The Ancient Neanderthal Hand in Severe COVID-19 - SciTechDaily

The genetics of poop and how it can help our health and threaten our privacy – Genetic Literacy Project

Everyone pees and poops. We excrete metabolites, vitamins, microbes, and even our own cells. This information makes its way into a wastewater treatment plant, creating a community-wide stool or urine sample. Wastewater epidemiologists can leverage our waste to detect disease outbreaks, drug use, and more. So what exactly can we detect and how is this information protected?

However, using sewage to monitor a communitys lifestyle and general health may seem, to many, more intrusive than monitoring disease outbreaks. At the University of Queensland, scientists were able topredict socioeconomic information using wastewater.This group of researchers used biomarkers from wastewater to predict 37 characteristics from the Australian Census including median age, education, and employment.

The Sewage Analysis CORe group Europe put together a set ofguidelines addressing ethical research practices for sewage epidemiologynoting that theres historically been little oversight by research ethics committees as wastewater data is not collected on individuals. Some of their mitigation strategies include aggregating samples from multiple sites, and removing names and locations of sampling sites.

Wastewater based epidemiology has the potential to gauge the health of our cities, but before reaping the benefits, scientists should also weigh and address the concerns. Sewer data used for research to understand population trends is much different from using the data for policy or punishment.

Read the original post

See the article here:
The genetics of poop and how it can help our health and threaten our privacy - Genetic Literacy Project

Pac-12 adds to RT-PCR COVID-19 testing capabilities with Fulgent Genetics partnership – Pac-12.com

New RT-PCR testing partnership to supplement existing testing capabilities across Pac-12 athletics departments

SAN FRANCISCO The Pac-12 today announced a conference-wide surveillance testing partnership for SARS-CoV-2 (COVID-19) with Fulgent Genetics (NASDAQ: FLGT) as part of its on-going student-athlete health & well-being initiatives (SAHWBI) efforts. Under the partnership, Fulgent Genetics will provide RT-PCR (reverse transcription polymerase chain reaction) testing capabilities to supplement existing PCR and antigen testing capabilities across each Pac-12 athletics department. The partnership follows and is in addition to the Pac-12s recently announced partnership with Quidel Corporation for daily rapid-results testing capabilities (point-of-care).

We are excited to be partnering with a leading testing company in Fulgent to provide our athletic departments with the very best capabilities to protect the health and well-being of our student-athletes, said Pac-12 Commissioner Larry Scott. On the heels of our agreement with Quidel to provide rapid-results testing, todays announcement represents another important step in providing a safe and healthy environment for a return to competition for our student-athletes.

Dr. Doug Aukerman, senior associate athletics director for Oregon State and chair of the Pac-12 SAHWBI added: Providing additional resources at the level of what Fulgent Genetics offers is a tremendous addition for our athletics departments and staff as we continue to strive for the most secure and safe environment for our student-athletes return to play.

Routine, rapid testing is playing a key role in limiting the spread of COVID-19 and is helping to keep players, coaches and staff safe as they look to return to competition. The Pac-12 has implemented several protocols in this area, and the RT-PCR testing provided by Fulgent Genetics is an important part of this process, said Brandon Perthuis, Chief Commercial Officer of Fulgent Genetics. RT-PCR is regarded as the gold standard in COVID-19 testing, providing the highest level of sensitivity and specificity. At Fulgent, we have built technology platforms around our test to make it scalable for the Pac-12, which allows us to deliver results within 24 hours of receipt of the sample for testing. We are excited to partner with the Pac-12 and look forward to helping keep their athletic programs running safely.

Each Pac-12 institution currently has RT-PCR testing practices and protocols in place for their athletics departments. With the new partnership, Fulgent Genetics will be able to serve as a supplemental resource for each athletics department. The RT-PCR testing program from Fulgent Genetics will be driven by the new Fulgent Enterprise COVID-19 Screening Platform, which provides an end-to-end solution for routine and repeat testing, including onsite testing for student-athletes and staff, 24-hour results and mobile delivery and interface.

For more information about COVID-19 testing options from Fulgent Genetics please visit fulgentgenetics.com/COVID19.

About the Pac-12 Student-Athlete Health and Well-Being Initiative

Created in 2013, the Pac-12 Student-Athlete Health and Well-Being Initiative (SAHWBI) is a collective effort between the Pac-12 and all 12 member universities to find ways to reduce injuries, share current best practices and latest studies and conduct research to uncover new ways to keep student-athletes as safe as possible. For more information, go to Pac-12.com/health.

Aboutthe Pac-12 Conference

The Conference has a tradition as the Conference of Champions, leading the nation in NCAA Championships in 54 of the last 60 years, with 529NCAA team titles overall. The Conference comprises 12 leading U.S. universities - the University of Arizona, Arizona State University, the University of California,Berkeley, the University of California at Los Angeles (UCLA), the University of Colorado, the University of Oregon, Oregon State University, Stanford University, the University of Southern California, the University of Utah, the University of Washington and Washington State University. For more information on the Conferences programs, member institutions, and Commissioner Larry Scott, go toPac-12.com/conference.

About Fulgent Genetics

Fulgent Genetics is a growing technology company with an initial focus on offering comprehensive genetic testing to provide physicians with clinically actionable diagnostic information they can use to improve the quality of patient care. The company has developed a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools and integrated laboratory processes. This platform allows the company to offer a broad and flexible test menu and continually expand and improve its proprietary genetic reference library, while maintaining accessible pricing, high accuracy and competitive turnaround times. The company believes its current test menu, which includes approximately 18,000 single-gene tests and more than 850 pre-established, multi-gene, disease-specific panels, offers more genes for testing than its competitors in todays market, which enables it to provide expansive options for test customization and clinically actionable results.

Follow this link:
Pac-12 adds to RT-PCR COVID-19 testing capabilities with Fulgent Genetics partnership - Pac-12.com

Research in Manitoba and Saskatchewan looking at genetics to help fight COVID-19 pandemic – CTV News Winnipeg

WINNIPEG -- New research out of the Prairies will be producing genomic data to help inform public health decisions during the COVID-19 pandemic.

On Sept. 29, Genome Prairie announced the launch of its Canadian COVID-19 Genomics Network (CanCOGeN) research projects, which will take place in Manitoba and Saskatchewan.

CanCOGeN, which was first announced in April 2020, is a $40-million network involving federal, provincial, and regional public health authorities, as well as academia and industry. The goal of the network is to coordinate and fund coronavirus and host genome sequencing efforts and to share and analyze the data.

Genome Prairie is proud to launch today, our two regional CanCOGeN projects: one in the Cadham Provincial Lab in Winnipeg and one in the Roy Romanow Provincial Lab in Regina, said Gerry Brown, interim president and CEO of Genome Prairie.

Both these invaluable projects have the capability to have a rapid and material impact on evolving COVID-related challenges.

The two projects are called the Virus Genome Sequencing Project (VirusSeq) and the Host

Genome Sequencing Project (HostSeq).

VirusSeq will focus on large-scale whole-genome sequencing, identifying genetic mutations and variations. This data will help with COVID-19 surveillance, contact tracing, tracking, dispersal, and management.

HostSeq involves whole genome sequencing of infected people in order to understand the clinical responses to infection, which range from mild discomfort to serious respiratory complications.

It is with no doubt that as we continue to fight against COVID-19, Genome Prairies expertise and leadership is needed to help us resolve and better understand the many COVID-19-related challenges we are faced with today, said MP Terry Duguid.

Duguid added these projects will gather scientific data to help better protect Canadians from this virus.

Genome Prairie is also working on its COV3R project, which is looking at the issue of detecting co-infections and providing new tools for public health.

See the article here:
Research in Manitoba and Saskatchewan looking at genetics to help fight COVID-19 pandemic - CTV News Winnipeg

Study shows clear links between genetic predisposition of CVD and lifestyle factors – News-Medical.Net

Reviewed by Emily Henderson, B.Sc.Sep 28 2020

From Weight Watchers to wearable tech wherever we look, there are messages encouraging us to stay fit and healthy.

But diets and training methods aside, when it comes to heart health, research from the University of South Australia shows that a far more personalized approach is neededand it all starts with your genes.

Conducted in partnership with the University of New England and the University of Queensland, the study assessed the impact of lifestyle factors on cardiovascular disease (CVD), finding clear links between genetic predisposition of CVD and smoking, alcohol intake, physical activity and diet.

UniSA researcher, Associate Professor Hong Lee, leader of the statistical genetics group at the Australian Centre for Precision Health, says the popular 'one-size-fits-all' approach to heart health does not have uniform effects, and that a tailored, individualised approach to CVD is essential.

Globally, CVD is the number one cause of death, claiming an estimated 17.9 million lives a year. Most deaths are due to heart attacks and strokes, with a third of these occurring prematurely in people under 70 years of age. In Australia, heart disease kills one Australian every four minutes.

"Every day, we're exposed to information that promotes positive lifestyle factors for better health. But what we don't hear, is how individual genetic differences can negate positive effects, often to detriment of the individual," Assoc Prof Lee says.

"Between 20 to 60 percent of risk factors for CVD are attributed to genetics which are far better addressed through personalised and individual interventions than broad-stroke lifestyle adjustments.

"For example, genetics show how the level of your cholesterol can be controlled by a lifestyle modification, given your genotypes and the underlying genetic link between cholesterol and lifestyle factors.

"This will help you make a decision about which lifestyle intervention is most suitable for you, for example, more exercise might be a better choice than reducing smoking.

"However, this does not necessary mean that exercise is uniformly recommended for other people who may have different genes and genetic effects that are more sensitive to smoking exposure.

"It's all about understanding how individual genetic risks can change in line with different lifestyle adjustments, and consequently how cardiovascular health can benefit."

Using a novel whole-genome approach, researchers analyzed 23 cardiovascular health-related traits and 22 lifestyle characteristics using the ARIC (Atherosclerosis Risk in Communities) Study (N=8291) and validating results via the UK Biobank (N~500,000). 34 significant CVD trait-lifestyle pairs were identified.

While Assoc Prof Lee agrees that positive lifestyle changes are good for overall health, including cardiovascular health, he says tailored interventions based on individual differences will be most successful for managing CVD.

As precision health practices advance, we are likely to see more personalised health treatments that are based on individual genetic profiles."

Hong Lee, Researcher and Associate Professor, University of South Australia

"We are currently in the process of developing tools that can predict genetic risk based on genotypes and how lifestyle changes can modulate these.

"Incorporating individual (genetic) differences into CVD interventions will absolutely increase the predictive power of lifestyle changes on individual health."

Source:

Journal reference:

Zhou, X., et al. (2020) WholeGenome Approach Discovers Novel Genetic and Nongenetic Variance Components Modulated by Lifestyle for Cardiovascular Health. Journal of the American Heart Association. doi.org/10.1161/JAHA.119.015661.

Read the rest here:
Study shows clear links between genetic predisposition of CVD and lifestyle factors - News-Medical.Net

Study into left-handedness finds 41 genetic variants that influence it – ABC News

About 10 per cent of Australians are left-handed and genetic analysis of more than 1.7 million people has brought scientists a step closer to understanding why.

Researchers from QIMR Berghofer Medical Research Institute and the University of Queensland have identified 48 genetic variants that influence if a person is left-handed, right-handed or ambidextrous.

Forty-one variants were linked to left-handedness and seven were associated with ambidexterity.

"Handedness is one of those things where both genetics and environment play a large role and what we've been able to do is advance the knowledge quite a bit further in the genetics side," Professor Sarah Medland from QIMR Berghofer's Psychiatric Genetics Group said.

"Each of these [variants] are just little changes in the DNA each of them individually have very, very small effects but when you consider all the effects together, they start to add up."

Researchers tapped into international biobanks to analyse genetic data from more than 1.7 million samples, making it one of the largest investigations of its kind.

The findings were published in the journal Nature Human Behaviour.

Professor Medland said environmental factors play a larger role than genes in determining which hand a person favours.

"Something like height is much more strongly genetically-influenced, whereas [for] something like handedness the genetic influences are relatively weak," she said.

"Through training or just through interacting with the environment and using tools that are designed one way or the other, you can actually influence someone's handedness quite a lot."

Professor Medland said the research also dispelled the belief that ambidextrousness was a middle-zone between left and right-handedness.

"The results from our study shows there was not very much genetic overlap actually between left-handedness and ambidextrousness it seems like there are different mechanisms going on there," she said.

She said more research was needed to help answer why people developed a dominant hand.

"The reason why we do this work is to help us understand ourselves as humans and this characteristic of ourselves," Professor Medland said.

"Although we've found 41 variants influencing left-handedness and seven influencing ambidextrousness, there's a lot more out there to find."

Visit link:
Study into left-handedness finds 41 genetic variants that influence it - ABC News

Applied Biology in Collaboration with Researchers at University Hospital Ramon y Cajal Hospital Announce Results from Study of Androgen Receptor…

IRVINE, Calif.--(BUSINESS WIRE)--Applied Biology in collaboration with researchers at University Hospital Ramon y Cajal in Madrid, Spain, today announced results from their androgen receptor genetics study in hospitalized COVID-19 male patients (NCT04368897, https://clinicaltrials.gov/ct2/show/NCT04368897?term=androgen&cond=Covid19&draw=2&rank=4). The aim of the study was to confirm a direct association between androgens and COVID-19, potentially paving the way for a breakthrough therapy against SARS-CoV-2.

This prospective longitudinal study analyzed the length of a variable genetic repeat in the androgen receptor gene of hospitalized COVID-19 male patients. The results of the clinical study were published in the Journal of the European Academy of Dermatology and Venerology (doi: 10.1111/jdv.16956).

The study demonstrated that the proportion of male patients admitted to the ICU with the longer variant was statistically significantly higher compared to males with the shorter variant. Similarly, the risk of ICU admissions was significantly higher among males with the longer variant (OR 2.9143). In addition, COVID-19 patients with the shorter variant experienced a shorter duration of hospitalization compared to males with the longer variant (25 days vs 47.5 days). Overall, the longer variant of the androgen receptor was associated with higher disease severity among hospitalized male COVID-19 patients.

The team was led by Andy Goren, MD, Medical Researcher and Co-Investigator with the Department of Dermatology at the University Hospital Ramon y Cajal in Madrid, Spain; Sergio Va Galvn, MD, from the Department of Dermatology at the University Hospital Ramon y Cajal; Sabina Herrera, MD, from the Infectious Disease Department at the University Hospital Ramon y Cajal; Carlos G. Wambier, MD, PhD, from the Department of Dermatology at the Alpert Medical School of Brown University; and Flavio A. Cadegiani, MD, MSc, PhD, from Corpometria Institute in Brazil.

According to Dr. Sergio Va Galvn: To the best of our knowledge, this is the first study to directly confirm an association between androgens and COVID-19 disease severity.

According to Dr. Carlos Wambier: This is another piece of the puzzle for the scientific understanding of role of androgens in the pandemic.

Further, according to Dr. Andy Goren: The results of this study further support our research into the use of anti-androgens in the treatment of COVID-19. If randomized prospective trials demonstrate efficacy, anti-androgens may provide a breakthrough inexpensive treatment for COVID-19.

ABOUT APPLIED BIOLOGY

Founded in 2002, Applied Biology, Inc. (www.appliedbiology.com), headquartered in Irvine, California, is a biotechnology company specializing in hair and skin science. Applied Biology develops breakthrough drugs and medical devices for the treatment of androgen mediated dermatological conditions. Applied Biology's R&D pipeline includes a topically applied prophylactic treatment for chemotherapy induced alopecia; a novel diagnostic device that can aid dermatologists in identifying non-responders to topical minoxidil; an adjuvant therapy for non-responders to topical minoxidil; and a novel therapy for female pattern hair loss.

See the original post:
Applied Biology in Collaboration with Researchers at University Hospital Ramon y Cajal Hospital Announce Results from Study of Androgen Receptor...

Genetic testing helps patients be proactive in seeking healthcare – The Columbus Dispatch

Megan Henry|The Columbus Dispatch

Joan Swarts recently learned she has a greater risk of developing colon, ovarian and breast cancer.

Genetic testing counselors at OhioHealth were able to discover all of this information after taking ablood sample from her back in February.

Now, Swarts, 55, of Delaware,is being proactive. She recently met with a colorectal surgeon and knows to increase the frequency of her colon screenings.

Im glad that I now know thats a potential and I can take steps to watch for that to catch it early, she said.

Genetic testing recognizes changes in chromosomes, genes or proteins. The results can help confirm or dismiss a suspected genetic condition;help determine a persons chance of developing a genetic condition; and show the likelihood of passing on a genetic disorder, according to the National Library of Medicine.

What we hope is that the genetic testing information is going to give us a very personalized plan for what that person needs to do based on their genetic testing results and based on their family history, said Amy Sturm, a cardiovascular genetics expert for the National Society of Genetic Counselors.

Test results come back either positive (meaning the test found a genetic change known to cause disease),negative (meaning the test did not find a genetic change known to cause disease), oruncertain (meaning there isn't enough information about the genetic change to figure out if it's normal or could cause a disease), according to the Centers for Disease Control and Prevention.

The results can answer questions like, Are there things that I can do that will enable me to not develop this disease? Or that can basically modify my risk or things that I can do to prepare myself for what might come in the future because I have this genetic condition? said Nichole Morman, genetic counseling manageratOhioHealth.

The number of licensed genetic counselors in Ohio has been on the rise. There were 221 in 2016 and 423 in June of this year, according to the state medical board annual report.

People do genetic testing for a variety of reasons. Somemight wonder whether they are predisposed to a genetic condition if they have a family history. Or a person might want to know why they were diagnosed with a specific condition. They might also question whether they could pass on a genetic condition to a child.

Breast cancer runs in Swarts'family. Her grandmother died from breast cancer when she was 65, so Swarts'breast health doctor urged her to do genetic testing.

(The genetic testing)was really informative,"Swarts said."I felt like I was inundated with a lot of information but everything has been explained really well to me as far as preventive things I need to do.

Erin Pettegrew, 46, did genetic testing a couple of years ago after her mom was diagnosed with ovarian cancer seven years ago.

TheHilliard resident had the tests through the Making Genetic Testing Accessible (Magenta) study, an at-home screening for 19 genetic abnormalitieslaunched out of the University of Texas MD Anderson Cancer Center.

She saw an ad for Magenta pop up on her Facebook and sent in her cheek swab after getting the kit. She got her results back a few weeks later saying she didnt have a genetic predisposition to ovarian cancer.

My heart was pounding as I opened the email for sure, but once I saw that it was negative it was a big relief, Pettegrew said. If it had been positive, I would have had to make some choices about maybe having my ovaries removed early in life and other considerations about my own health, but I didnt have to go down that path."

There is a psychological aspect tofinding out whether you're predisposed to a genetic condition, Morman noted.

How is that going to make me feel about myself? How is it going to impact my relationships with my family members?" Morman said.

Swarts's mind is more at ease knowing she has the potential for these diseases and she takes comfort knowing it can be caught early.

"Honestly, Im one of those people who thought I really dont want to know so I was nervous about doing it, but Im glad I did so I can take the necessary measures to look for this stuff,"Swarts said.

Direct-to-consumertesting like 23andMe is also an option, but the results can be limited.

If you are interested in doing genetic testing because of a family health history of a certain disease, we do not recommend doing a 23andMe test, rather you should speak to your health-care provider,Aushawna Collins, 23andMe spokesperson, said in an email.

Genetic testing is continuing to evolve and whole-genome sequencing for newborns could be on the horizon.

A baby is born and you want to know for that baby's entire life what might they be at risk for, Sturm said. I think really getting that full genome sequencing at a very young age and then using it as a resource throughout their life is something we really are striving toward in our field.

mhenry@dispatch.com

@megankhenry

Read this article:
Genetic testing helps patients be proactive in seeking healthcare - The Columbus Dispatch